NPM1-mut AML patients with concomitant DNMT3A mutations, responding optimally to standard induction chemotherapy, despite the persistence of the DNMT3A mutations, achieved a long-term response [30,31]. This evidence concerns the gene NPM1 and acute myeloid leukemia.